CDMO News
WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing
WuXi Biologics has announced the successful scale-up of its proprietary WuXiUI™ platform to 2,000L GMP manufacturing, marking a significant milestone in biologics production. This achievement, which utilises the company’s ultra-intensified fed-batch bioprocessing technology, has resulted in a fourfold increase in
2 September 2024
Stay ahead of trends and best practices
